Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1996-05-06
1998-04-28
Peselev, Elli
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 64, A61K 3170, C07H 1524
Patent
active
057444544
DESCRIPTION:
BRIEF SUMMARY
The present invention relates to treating amyloidosis, to novel compounds for such treatment, to processes for their preparation and to pharmaceutical compositions containing them.
The relationship between amyloidosis, cell death and loss of tissue function appears to be of relevance for different types of disorders including neurodegenerative disorders. Therefore, the prevention of amyloid formation and/or the induction of amyloid degradation can be an important therapeutic tool for all pathological disorders associated with amyloidosis including AL amyloidosis and neurodegenerative disorders of the Alzheimer's type.
More particularly, the present invention provides the use in the manufacture of a medicament for use in the treatment of amyloidosis of an anthracycline of formula A ##STR1## wherein R.sub.1 represents: hydrogen or hydroxy; C.sub.5 -C.sub.6 cycloalkyl or CH.sub.2 Ph, with the phenyl (Ph) ring optionally substituted by 1, 2 or 3 substituents selected from F, Cl, Br, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy and CF.sub.3 ; or alkyl or Ph optionally substituted by 1, 2 or 3 substituents selected from halogen such as F, Cl or Br, and C.sub.1 -C.sub.6 alkyl; above defined; in which Y is CO, CH.sub.2, CHOH or a group of formula ##STR2## in which m is 2 or 3 and R.sub.6 is: hydrogen or hydroxy; substituted with hydroxy, CN, COR.sub.9, COOR.sub.9, CONR.sub.9 R.sub.10, O(CH.sub.2).sub.n NR.sub.9 R.sub.10 (n is 2 to 4) or NR.sub.9 R.sub.10, in which R.sub.9 and R.sub.10 are each independently selected from hydrogen, C.sub.1 -C.sub.12 alkyl, C.sub.2 -C.sub.12 alkenyl or phenyl optionally substituted by one or more, for example 1, 2 or 3, substituents selected from C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, F, Br, Cl, CF.sub.3, OH, NH.sub.2 or CN, COOR.sub.9 or OH, wherein R.sub.9 is as above defined, optionally substituted on the phenyl ring by one or more, for example 1, 2 or 3, substituents selected from C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, F, Br, Cl, CF.sub.3, OH, NH.sub.2 or CN, and R.sub.10, CONR.sub.9 COOR.sub.10 or SO.sub.2 R.sub.9 in which R.sub.9 and R.sub.10 are as defined above, or C.sub.1 -C.sub.4 alkoxy, C.sub.2 -C.sub.6 alkenyl or phenyl optionally substituted by one or more, for example 1, 2 or 3, substituents selected from C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, F, Br, Cl, CF.sub.3, OH, NH.sub.2 or CN, and substituted by OH, NH.sub.2, COOH, COOR.sub.9 or CONR.sub.9 R.sub.10 wherein R.sub.9 and R.sub.10 are as above defined, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl or phenyl optionally substituted by one or more, for example 1, 2 or 3, substituents selected from C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, F, Br, Cl, CF.sub.3, OH, NH.sub.2, or CN; defined; substituted by nitro, amino or NR.sub.7 R.sub.8 as above defined; or ##STR3## wherein D is a group of formula COOR.sub.9 or CONR.sub.7 R.sub.8 in which R.sub.7, R.sub.8 and R.sub.9 are as above defined; and ##STR4## wherein: R.sub.11 and R.sub.12 are both hydrogen or one of R.sub.11 and R.sub.12 is hydrogen and the other is F, Cl, Br or I; NHCOCF.sub.3, N=C(C.sub.6 H.sub.5).sub.2, NHCOR.sub.9, NHCONR.sub.7 R.sub.8 or a group of formula E or F ##STR5## in which R.sub.7, R.sub.8 and R.sub.9 are as above defined and p is 0 or 1; is hydrogen and the other is OH, F, Cl, Br, I or a group of formula OSO.sub.2 R.sub.5 wherein R.sub.5 is as above defined; wherein R.sub.5 is as above defined; the compound of the formula A is not 4'-iodo-4'-deoxy-doxorubicin (R.sub.1 .dbd.OCH.sub.3, R.sub.2 .dbd.OH, R.sub.3 .dbd.COCH.sub.2 OH, X.dbd.X.sub.1, R.sub.11 .dbd.R.sub.12 .dbd.R.sub.15 .dbd.H, R.sub.13 .dbd.NH.sub.2 and R.sub.14 .dbd.I).
In a further aspect of the present invention there are provided novel anthracyclines of the formula A as above defined, wherein: hydrogen atoms or one of R.sub.14 or R.sub.15 is hydroxy and R.sub.13 is amino when R.sub.3 is a group of formula YCH.sub.3, COCH.sub.2 NR.sub.7 'R.sub.8 ', COCH.sub.2 R'.sub.4 or YCH.sub.2 OH, wherein Y is as above defined, R'.sub.4 is phenyl, benzyl
REFERENCES:
patent: 5637572 (1997-06-01), Merlini et al.
Y. Levy, et al., Traitement de L'amylose Al. sans myelome Ann. Med. Interne, vol. 139 -1988 No. 3.
Ballinari Dario
Bargiotti Alberto
Caruso Michele
Lansen Jacqueline
Suarato Antonino
Peselev Elli
Pharmacia & Upjohn S.p.A.
LandOfFree
Anthracycline derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anthracycline derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anthracycline derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1532046